NDAINTRAVENOUSPOWDER
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBATIV (telavancin hydrochloride) is a lipoglycopeptide antibiotic administered intravenously for treatment of complicated skin and soft tissue infections (cSSTI) and hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). It is a semi-synthetic derivative of vancomycin designed to enhance bacterial cell wall inhibition through improved penetration and binding.
$0.782MPart D
LOE Approaching8mo to LOEMinimal market traction with only $782K in Part D spending suggests small, specialized brand team focused on hospital formulary management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
VIBATIV Pregnancy Registry
Started Nov 2009
0Pregnancy
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on VIBATIV at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.